<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146144</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0026</org_study_id>
    <nct_id>NCT02146144</nct_id>
  </id_info>
  <brief_title>Prospective, Single-blind Study Assessing the Benefit/Risk Ratio of Internal Limiting Membrane (ILM) Peeling During Epimacular Membrane (EMM) Surgery (Peeling)</brief_title>
  <acronym>Peeling</acronym>
  <official_title>Prospective, Randomized, Controlled and Single-blind Study Assessing the Benefit/Risk Ratio of Internal Limiting Membrane (ILM) Peeling During Epimacular Membrane (EMM) Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The epimacular membrane (EMM) is a degenerative condition associated with age, with a&#xD;
      variable impact on vision. Treatment is surgery based and consists of a vitrectomy followed&#xD;
      by a peeling of the epimacular membrane using a microgripper. Peeling of the internal&#xD;
      limiting membrane (ILM) is an adjuvant action that is now frequently practiced and which is&#xD;
      expected to increase the success rate of EMM surgery by reducing the risk of recurrence of&#xD;
      EMM. Although ILM peeling does not seem to have an adverse effect on visual acuity, it is not&#xD;
      totally without consequence, it involves the risk of histological disorganization of the&#xD;
      retina at the origin of one or several microscotomas, which are themselves responsible for a&#xD;
      final visual discomfort. These microscotomas, resulting in the perception of somewhat black&#xD;
      spots visible near the fixed point or the fixed image, may be highlighted by microperimetry&#xD;
      and would be a loss of functional opportunity for the patient.&#xD;
&#xD;
      In addition, recurrence of EMM, which the ILM peeling is supposed to diminish, does not alter&#xD;
      the vision in half the patients. Furthermore, for those patients who are functionally&#xD;
      affected by any such recurrence, a second epimacular membrane peeling surgery can be done.&#xD;
&#xD;
      The main objective of this study is to compare the difference in microscotoma(s) before&#xD;
      surgery and 6 months later, between an &quot;active ILM peeling&quot; group and a &quot;no ILM peeling&quot;&#xD;
      group. Given the more invasive nature of ILM peeling, the investigators believe that the rate&#xD;
      of microscotomas in these patients is higher than those without peeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The visits for this trial are those planned for patients receiving EMM surgical operation,&#xD;
      namely:&#xD;
&#xD;
      Selection/Inclusion visit : D-90 to D-7 This visit can be split in two according to the&#xD;
      requirements of the investigator and/or the patient.&#xD;
&#xD;
        -  Full information about the trial&#xD;
&#xD;
        -  Verification of the inclusion and non-inclusion criteria&#xD;
&#xD;
        -  Obtaining the signed informed consent (the same day or after a period of reflection)&#xD;
&#xD;
        -  Medical and surgical history - *Examination: Visual acuity measured on the ETDRS scale,&#xD;
           near vision (Parinaud), spectral domain optical coherence tomography (SD-OCT),&#xD;
           microperimetry and pre-operative: &quot;Patient discomfort&quot; questionnaire (Appendix 7), an&#xD;
           assessment of the appearance of the lens at the slit lamp, examination of the fundus&#xD;
           after pupillary dilation, biomicroscopic examination of the anterior segment, retinal&#xD;
           photography.&#xD;
&#xD;
      Surgery visit D0:&#xD;
&#xD;
        -  List of all the surgical procedures&#xD;
&#xD;
        -  Randomization for ILM peeling or not, in the operating room after dyeing of the ILM by&#xD;
           the Membraneblue-Dual® (Picture of the macula). An anonymous video of the surgery will&#xD;
           be sent to Nantes for centralized processing of the analysis of the EMM's grip areas.&#xD;
&#xD;
      To avoid bias, the follow-up visits will be made by an ophthalmologist and/or an orthoptist&#xD;
      who will not know what action has been performed.&#xD;
&#xD;
      Follow-up visit M1 (1 month after the surgery ± 7 days)&#xD;
&#xD;
        -  Examination: Visual acuity measured on the ETDRS scale, near vision (Parinaud), spectral&#xD;
           domain optical coherence tomography (SD-OCT), Microscopic examination of the eye,&#xD;
           microperimetry, fundus photography and post-operative &quot;Patient discomfort&quot; questionnaire&#xD;
           (Appendix 8). Biomicroscopic examination of the anterior segment, retinal photography.&#xD;
&#xD;
        -  AE&#xD;
&#xD;
      Follow-up visit M6 (6 months after the surgery ± 15 days)&#xD;
&#xD;
        -  Examination: Visual acuity measured on the ETDRS scale, near vision (Parinaud), spectral&#xD;
           domain optical coherence tomography (SD-OCT), Microscopic examination of the eye,&#xD;
           microperimetry, fundus photography and post-operative: &quot;Patient discomfort&quot;&#xD;
           questionnaire (Appendix 8). Biomicroscopic examination of the anterior segment, retinal&#xD;
           photography.&#xD;
&#xD;
        -  AE End of study visit M12 (12 months after the surgery ± 15 days)&#xD;
&#xD;
        -  Examination: Visual acuity measured on the ETDRS scale, near vision (Parinaud), spectral&#xD;
           domain optical coherence tomography (SD-OCT), Microscopic examination of the eye,&#xD;
           microperimetry, fundus photography and post-operative &quot;Patient discomfort&quot; questionnaire&#xD;
           (Appendix 8), Biomicroscopic examination of the anterior segment, retinal photography.&#xD;
&#xD;
        -  AE&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference in microscotomas between the inclusion visit and the visit at 6 months after surgery.</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of the primary endpoint: the main criterion is the difference between the number of microscotomas measured before surgery and the number of microscotomas measured at 6 months (number between 0 and 29).&#xD;
The mean difference will be calculated in each of two groups and compared using a mixed model of linear regression to take into account the stratification of the randomization at the center (the center will be considered as a random effect)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of anatomical and functional changes of the retina</measure>
    <time_frame>12 months</time_frame>
    <description>Number and types of microscotomas by microperimetry (before and after surgery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the rate of EMM recurrence (at M12) between the 2 groups.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Idiopathic Epimacular Membrane</condition>
  <arm_group>
    <arm_group_label>no peeling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>where the ILM peeling will not be made</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active peeling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>where the ILM peeling will be made</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ILM Peeling</intervention_name>
    <description>common surgical procedure:&#xD;
For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens&#xD;
For all patients:&#xD;
Central and peripheral 25 Gauge vitrectomy&#xD;
dissection of the epimacular membrane&#xD;
injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity&#xD;
Intraoperative picture to see the possible spontaneous ILM peeling&#xD;
If no spontaneous ILM peeling, the patient will be randomized at the operating block&#xD;
Specific surgical procedure:&#xD;
• • Randomization into two groups:&#xD;
Arm 1: &quot;no peeling&quot;, where the ILM peeling will not be made&#xD;
Arm 2: &quot;active peeling&quot;, where the ILM peeling will be made</description>
    <arm_group_label>active peeling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;18 years old) and female without childbearing potential or active&#xD;
             contraception (intra-uterine device, contraceptive pill or contraceptive implant).&#xD;
&#xD;
          -  Patients with an idiopathic symptomatic epimacular membrane; for patients with both&#xD;
             eyes affected, the eye treated in the protocol will be the one which is most severely&#xD;
             affected.&#xD;
&#xD;
          -  Pseudophakic patients with transparent posterior capsule or open capsule or lensed&#xD;
             patients with age-related cataracts&#xD;
&#xD;
          -  Patients with social security&#xD;
&#xD;
          -  Patients able to understand and follow the trial instructions&#xD;
&#xD;
          -  Patients who have signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with other retinal pathologies such as age related macular degeneration&#xD;
             (&quot;AMD&quot;), retinal vein occlusion, diabetic retinopathy, glaucoma with macular visual&#xD;
             field defect&#xD;
&#xD;
          -  Patients with uveitis or history of uveitis&#xD;
&#xD;
          -  Patients with any recent eye injuries or eye surgeries (&lt;6 months)&#xD;
&#xD;
          -  Patients participating in interventional clinical trial&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Vulnerable people : persons deprived of liberty; under trusteeship or under&#xD;
             curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramin Tadayoni, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Lariboisière, AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Creuzot-Garchet, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yannick Le Mer, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Pr Weber, Pr</last_name>
    <phone>0661180456</phone>
    <email>michel.weber@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Creuzot-Garchet, Profesor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Sourdille</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Becquet Franck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Weber, Profesor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick Le Mer, Profesor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière (AP-HP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin Tadayoni, Profesor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de l'atlantique</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lignereux François</last_name>
    </contact>
    <contact_backup>
      <email>françois.ligneureux@free.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic epimacular membrane</keyword>
  <keyword>internal limiting membrane peeling</keyword>
  <keyword>microscotomas</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

